NO2743348T3 - - Google Patents

Info

Publication number
NO2743348T3
NO2743348T3 NO12821758A NO12821758A NO2743348T3 NO 2743348 T3 NO2743348 T3 NO 2743348T3 NO 12821758 A NO12821758 A NO 12821758A NO 12821758 A NO12821758 A NO 12821758A NO 2743348 T3 NO2743348 T3 NO 2743348T3
Authority
NO
Norway
Application number
NO12821758A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2743348T3 publication Critical patent/NO2743348T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO12821758A 2011-08-11 2012-08-10 NO2743348T3 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトngf抗体

Publications (1)

Publication Number Publication Date
NO2743348T3 true NO2743348T3 (enExample) 2018-06-09

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12821758A NO2743348T3 (enExample) 2011-08-11 2012-08-10

Country Status (30)

Country Link
US (2) US8986952B2 (enExample)
EP (1) EP2743348B1 (enExample)
JP (1) JP5376095B2 (enExample)
KR (1) KR101999867B1 (enExample)
CN (1) CN103748222B (enExample)
AR (1) AR087506A1 (enExample)
AU (1) AU2012293161B2 (enExample)
BR (1) BR112014002576B1 (enExample)
CA (1) CA2841181C (enExample)
CY (1) CY1119914T1 (enExample)
DK (1) DK2743348T3 (enExample)
EA (1) EA024292B1 (enExample)
ES (1) ES2663968T3 (enExample)
HR (1) HRP20180155T1 (enExample)
HU (1) HUE036079T2 (enExample)
IL (1) IL230797A (enExample)
IN (1) IN2014CN00614A (enExample)
LT (1) LT2743348T (enExample)
ME (1) ME02944B (enExample)
MX (1) MX351273B (enExample)
NO (1) NO2743348T3 (enExample)
PH (1) PH12014500001A1 (enExample)
PL (1) PL2743348T3 (enExample)
PT (1) PT2743348T (enExample)
RS (1) RS56876B1 (enExample)
SI (1) SI2743348T1 (enExample)
SM (1) SMT201800166T1 (enExample)
TW (1) TWI554519B (enExample)
WO (1) WO2013022083A1 (enExample)
ZA (1) ZA201400741B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトngf抗体
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
BR112017025029A2 (pt) * 2015-05-22 2018-08-07 Astellas Pharma Inc. ?novo fragmento fab de anticorpo ngf anti- humano?.
JPWO2017164349A1 (ja) * 2016-03-25 2019-02-07 アステラス製薬株式会社 PEG化抗ヒトNGF抗体Fab’フラグメント含有医薬組成物
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技(上海)有限公司 抗人ngf抗体及其制备方法和用途
US20210147529A1 (en) 2018-05-15 2021-05-20 Astellas Pharma Inc. Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
KR100337069B1 (ko) * 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1684708A (zh) 2001-05-30 2005-10-19 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
NZ556157A (en) 2005-01-24 2009-09-25 Elan Pharma Int Ltd Specific binding members for NGF
RS53661B1 (sr) * 2007-08-10 2015-04-30 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
RU2461551C2 (ru) 2007-10-24 2012-09-20 Астеллас Фарма Инк. Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability

Also Published As

Publication number Publication date
CA2841181C (en) 2022-01-25
HUE036079T2 (hu) 2018-06-28
AR087506A1 (es) 2014-03-26
IN2014CN00614A (enExample) 2015-04-03
US8986952B2 (en) 2015-03-24
MX351273B (es) 2017-10-06
CY1119914T1 (el) 2018-06-27
LT2743348T (lt) 2018-05-10
CA2841181A1 (en) 2013-02-14
JPWO2013022083A1 (ja) 2015-03-05
EA024292B1 (ru) 2016-09-30
IL230797A0 (en) 2014-03-31
ES2663968T3 (es) 2018-04-17
SMT201800166T1 (it) 2018-05-02
SI2743348T1 (en) 2018-04-30
PL2743348T3 (pl) 2018-04-30
US20150218265A1 (en) 2015-08-06
CN103748222A (zh) 2014-04-23
KR101999867B1 (ko) 2019-07-12
TWI554519B (zh) 2016-10-21
EP2743348B1 (en) 2018-01-10
IL230797A (en) 2017-06-29
JP5376095B2 (ja) 2013-12-25
EA201490433A1 (ru) 2014-05-30
ZA201400741B (en) 2014-11-26
CN103748222B (zh) 2015-07-22
EP2743348A1 (en) 2014-06-18
BR112014002576A2 (pt) 2021-01-12
EP2743348A4 (en) 2015-04-29
HRP20180155T1 (hr) 2018-03-23
TW201319086A (zh) 2013-05-16
DK2743348T3 (en) 2018-02-26
ME02944B (me) 2018-04-20
BR112014002576B1 (pt) 2022-08-23
PH12014500001A1 (en) 2014-02-10
PT2743348T (pt) 2018-02-23
US20140155582A1 (en) 2014-06-05
AU2012293161B2 (en) 2017-04-27
AU2012293161A1 (en) 2014-02-06
KR20140047116A (ko) 2014-04-21
WO2013022083A1 (ja) 2013-02-14
RS56876B1 (sr) 2018-04-30
MX2014001627A (es) 2014-05-28

Similar Documents

Publication Publication Date Title
BR112013022641A2 (enExample)
BR112013031251A2 (enExample)
BR112013027245A2 (enExample)
BR112013024383A2 (enExample)
BR112013023185A2 (enExample)
BR112013022995A2 (enExample)
BR112013026905A2 (enExample)
BR112013017670A2 (enExample)
BR112013027830A2 (enExample)
AP3853A (enExample)
BR112013026744A2 (enExample)
BR112013023927A2 (enExample)
BR112013027452A2 (enExample)
BR112013024365A2 (enExample)
BR112013028733A2 (enExample)
BR112013027121A2 (enExample)
AP2016009466A0 (enExample)
BR112013024588A2 (enExample)
BR112013031556A2 (enExample)
BR112013026790A2 (enExample)
BR112013032366A2 (enExample)
BR112013032377A2 (enExample)
BR112013032380A2 (enExample)
BR112013027836A2 (enExample)
BR112013018949A2 (enExample)